Intermuscular Adipose Tissue in CKD
Clinical Journal of the American Society of Nephrology · 2025-07 · 20 (7) · 1014-1027
DOI: 10.2215/cjn.0000000745 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 30.04.2025. Verfasst von Mert Demirci und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Muscle, Skeletal, Adipose Tissue. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, US Department of Veterans Affairs, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Patients with CKD often experience loss of muscle mass, altered muscle function, and low physical functionality, all of which contribute to increased mortality and morbidity. Mitochondrial dysfunction emerges early in the progression of CKD and may play a central role in physical dysfunction. Factors such as uremia, systemic inflammation, oxidative stress, and inappropriate activation of the renin-angiotensin-aldosterone system may play a role on mitochondrial dysfunction. On the other hand, the accumulation of ectopic adipose tissue in skeletal muscle, also known as intermuscular adipose tissue (IMAT), is a newly recognized factor in muscle function and physical performance. IMAT is a marker of muscle quality, adversely affecting local muscle function, and is associated with insulin resistance and systemic inflammation, conditions commonly observed in CKD. Nevertheless, the exact composition of IMAT and its relationship with mitochondria and muscle energetics in CKD is not fully understood. Evaluating the relationship between IMAT accumulation and mitochondrial dysfunction in CKD may unveil potential interventions to improve physical function and the quality of life of patients with CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
- Division of Nephrology, Department of Medicine, University of California, Davis, Davis, California.
- Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
ORCID-Profile: Mert Demirci, R Gulsah Dilaver, T Alp Ikizler, Jorge L Gamboa
Förderung
- NIDDK NIH HHS
- US Department of Veterans Affairs
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Demirci, M., Dilaver, R. G., Roshanravan, B., Ikizler, T. A., & Gamboa, J. L. (2025). Intermuscular Adipose Tissue in CKD. Clinical Journal of the American Society of Nephrology, 20(7), 1014-1027. https://doi.org/10.2215/cjn.0000000745
Vancouver
Demirci M, Dilaver RG, Roshanravan B, Ikizler TA, Gamboa JL. Intermuscular Adipose Tissue in CKD. Clinical Journal of the American Society of Nephrology. 2025;20(7):1014-1027. doi:10.2215/cjn.0000000745
BibTeX
@article{Demirci2025,
author = {Demirci, Mert and Dilaver, R Gulsah and Roshanravan, Baback and Ikizler, T Alp and Gamboa, Jorge L},
title = {Intermuscular Adipose Tissue in CKD},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2025},
volume = {20},
number = {7},
pages = {1014--1027},
doi = {10.2215/cjn.0000000745}
}
EUVIMED